

**PTRF Antibody (N-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP7421a****Specification**

---

**PTRF Antibody (N-term) Blocking Peptide - Product Information**Primary Accession [Q6NZI2](#)**PTRF Antibody (N-term) Blocking Peptide - Additional Information****Gene ID** 284119**Other Names**

Polymerase I and transcript release factor, Cavin-1, PTRF {ECO:0000312|EMBL:AAH661231}

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP7421a](/products/AP7421a) was selected from the N-term region of human PTRF. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**PTRF Antibody (N-term) Blocking Peptide - Protein Information****Name** CAVIN1 ([HGNC:9688](#))**Synonyms** PTRF**Function**

Plays an important role in caveolae formation and organization. Essential for the formation of caveolae in all tissues (PubMed: [18056712](http://www.uniprot.org/citations/18056712), PubMed: [18191225](http://www.uniprot.org/citations/18191225), PubMed: [19726876](http://www.uniprot.org/citations/19726876)). Core component of the CAVIN complex which is essential for recruitment of the complex to the caveolae in presence of calveolin-1 (CAV1). Essential for normal oligomerization of CAV1. Promotes ribosomal transcriptional activity in response to metabolic challenges in the adipocytes and plays an important role in the formation of the ribosomal transcriptional loop. Dissociates transcription complexes paused by DNA-bound TTF1, thereby releasing both RNA polymerase I and pre-RNA from the template (By similarity) (PubMed: [CA](#)

href="http://www.uniprot.org/citations/18056712" target="\_blank">18056712</a>, PubMed:<a href="http://www.uniprot.org/citations/18191225" target="\_blank">18191225</a>, PubMed:<a href="http://www.uniprot.org/citations/19726876" target="\_blank">19726876</a>). The caveolae biogenesis pathway is required for the secretion of proteins such as GASK1A (By similarity).

#### **Cellular Location**

Membrane, caveola. Cell membrane. Microsome. Endoplasmic reticulum {ECO:0000250|UniProtKB:P85125}. Cytoplasm, cytosol. Mitochondrion. Nucleus Note=Translocates to the cytoplasm from the caveolae upon insulin stimulation (PubMed:17026959). Colocalizes with CAV1 in lipid rafts in adipocytes. Localizes in the caveolae in a caveolin-dependent manner (By similarity). {ECO:0000250|UniProtKB:O54724, ECO:0000269|PubMed:17026959}

#### **PTRF Antibody (N-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

#### **PTRF Antibody (N-term) Blocking Peptide - Images**

#### **PTRF Antibody (N-term) Blocking Peptide - Background**

Termination of transcription by RNA polymerase I involves pausing of transcription by TTF1, and the dissociation of the transcription complex, releasing pre-rRNA and RNA polymerase I from the template. PTRF is required for dissociation of the ternary transcription complex.

#### **PTRF Antibody (N-term) Blocking Peptide - References**

Aboulaich,N., Biochem. Biophys. Res. Commun. 350 (3), 657-661 (2006)Aboulaich,N., Biochem. J. 383 (PT 2), 237-248 (2004)Hasegawa,T., Biochem. J. 347 PT 1, 55-59 (2000)